RNAi-based therapeutics show promising clinical data for treatment of liver-associated disorders. However, siRNA delivery into extra-hepatic tissues remains an obstacle, limiting the use of siRNA-based therapies. Here we report on a first example of chemical engineering of lipophilic conjugates to enable extra-hepatic delivery. We synthesized a panel of fifteen lipophilic siRNA and evaluated the impact of their chemical configuration on siRNA tissue distribution profile. Generally, lipophilic conjugates allow siRNA distribution to a wide range of tissues, where the degree of lipophilicity defines the ratio of liver/spleen to kidney distribution.
Introduction
Therapeutic oligonucleotides-i.e., antisense oligonucleotides, small interfering RNA (siRNA), and aptamers-are emerging as a new class of drugs in addition to small molecules and biologics 1 . Their advantages over conventional drugs include: (i) ease of design, rationally achieved based on sequence information and straightforward screening, leading to drug candidates within short periods of time; (ii) ability to target disease genes previously considered "undruggable"; and (iii) unprecedented potency and duration of effect 2, 3 . Clinical success is dependent on their efficient delivery to disease tissues.
For liver delivery, the trivalent N-acetylgalactosamine (GalNAc) conjugate binds with high specificity and affinity to the asialoglycoprotein receptor on hepatocytes, leading to specific oligonucleotide delivery to and robust gene silencing in hepatocytes [4] [5] [6] [7] . This delivery strategy has revolutionized the development of oligonucleotide therapeutics to treat liver diseases, with more than a dozen clinical programs 8 . The success of the GalNAc platform demonstrates that functional tissue delivery of therapeutic oligonucleotides is a foundation for any clinical exploration.
Lipid nanoparticles (LNPs) have been successfully used for siRNA delivery in vivo. Most LNP formulations preferentially deliver siRNAs to liver but engineering the lipid composition of LNPs was shown to change their distribution, allowing functional delivery to endothelia, lung, and peritoneal macrophages 9, 10 . Thus, lipid moieties can be used to improve siRNA distribution.
Indeed, lipid conjugates have been explored to improve siRNA bioavailable. Cholesterol was the first lipid conjugate developed. After systemic administration, cholesterol-conjugated siRNAs preferentially distribute to liver 11, 12 , but are also distributed to other tissues, including muscle and placenta, where they can induce silencing (Turanov et al., in review) 13 . In addition, local injection of cholesterol-modified siRNAs leads to functional gene silencing in brain, vagina, and skin [14] [15] [16] [17] . Other lipid-conjugated siRNAs have been explored, including fatty acids 11 and vitamins (Vitamin E) 18 conjugated siRNA, but delivery and efficacy were only evaluated in liver.
Other than the conjugate, the design of the siRNA plays a crucial role in improving siRNA delivery. Indeed, unmodified siRNAs are rapidly degraded and cleared from circulation by kidney filtration, leading to minimal bioavailability in tissues 12 . Thus, full chemical stabilization of siRNAs is essential for conjugate-mediated delivery 19 . The clinical success of GalNAc conjugated siRNAs was only achieved when the siRNAs are extensively modified 20, 21 .
Chemical scaffolds that replace every 2' hydroxyl [22] [23] [24] , modify terminal nucleotide linkages 25, 26 , and stabilize the 5' phosphate [27] [28] [29] [30] maximize in vivo activity of siRNAs.
Here we systematically evaluate how lipid conjugates affect siRNA distribution in vivo.
We synthesized a panel of siRNAs conjugated to fifteen different lipophilic moieties, including saturated and non-saturated fatty acids, steroids, and vitamins, with or without a phosphocholine polar head group. We show that lipid conjugates enable siRNA accumulation and productive silencing in a wide range of tissues in mice after subcutaneous injection. In general, the degree of siRNA lipophilicity correlates with accumulation in kidneys (less lipophilic) or liver (more lipophilic). Though most of the injected siRNA accumulates in clearance organs, we identify conjugates that enable functional siRNA delivery to heart, lung, fat, muscle, and adrenal gland.
The tissue concentrations of siRNA required for productive silencing varied depending on the tissue and lipid conjugate. Our findings provide proof of principle for the development of lipidconjugated oligonucleotides as therapeutics for multiple indications.
Results

Synthesis of conjugated siRNAs library
To evaluate how the structures of lipid conjugates affect siRNA distribution in vivo, we synthesized a panel of siRNAs conjugated with naturally occurring lipids, including: the unsaturated fatty acids 22:6 n-3, docosahexaenoic acid (DHA) and 20:5 n-3, eicosapentaenoic acid (EPA); the saturated fatty acid 22:0, docosanoic acid (DCA); the sterols cholesterol (chol) and lithocholic acid (LA); and the vitamins retinoic acid (RA) and α-tocopheryl succinate (TS) (Figure 1) . A significant fraction of circulating fatty acids are esterified with phosphatidylcholine or other head groups 31, 32 . We therefore synthesized each lipid conjugate with or without a phosphocholine (PC) head group 33 , to test whether the polar head group affects the distribution profile of lipid-conjugated siRNAs in vivo. We also synthesized unconjugated siRNAs (Unconj.) and siRNAs with the PC head group (PC) but no lipid for controls. Each lipid conjugate was covalently attached to the 3′ end of the siRNA sense strand, which tolerates a range of covalent modifications 12, 34, 35 . The siRNAs used in these studies were fully chemically modified for maximal stability and minimal innate immune activation as described (see Figure   1a and Methods). We and others have recently shown that full chemical stabilization is essential for conjugated-mediated delivery [19] [20] [21] . The chemical compositions of lipids had a profound effect on the hydrophobicity of lipid-siRNA, based on retention time in reversed-phase HPLC 36 , which ranged from 1 to 12.2 minutes (Figure 1b) . In general, compounds with a PC head group eluted 0.5 to 1.3 min earlier than counterparts without a PC head group, suggesting that the PC head group reduces lipophilicity.
Oligonucleotides without a lipid eluted the fastest, with the PC-siRNA conjugate (1 min) eluting 4.7 min earlier than unconjugated oligonucleotide control (5.7 min). Lipid-conjugated siRNAs fell into two categories: low lipophilic compounds (retention times from 7.2 to 8.8 min) with unsaturated carbon chains or cyclic structures (LA, PC-LA, EPA, PC-EPA, RA, PC-RA, DHA, and PC-DHA conjugates); and high lipophilicity compounds (retention times from 10.2 to 12.2 min) with saturated carbon chains (TS, PC-TS, DCA, PC-DCA, chol. and PC-chol. conjugates).
Lipid conjugates define in vivo distribution of lipophilic siRNAs
To evaluate how the lipid moiety affects siRNA distribution to tissues, mice were injected subcutaneously with lipid-conjugated siRNA or PC-siRNA or unconjugated siRNA (3 mice per compound). The siRNA sense strands were labeled at their 5′-ends with a Cy3 fluorophore for qualitative analysis of tissue sections by fluorescence microscopy. We also quantified the concentrations of siRNA antisense strands in tissue biopsies using a peptide nucleic acid (PNA) hybridization assay 37, 38 . It is important to note that the PNA hybridization assay is not dependent on the presence of a Cy3 dye. Indeed, the levels of tissue accumulation of Cy3-labeled and non-labeled siRNA were compared for several conjugated siRNAs and were shown to be similar (data not shown). In addition, we have recently shown that conjugated siRNAs are cleared from the blood stream and accumulate in liver and kidneys within hours of injection, and the tissue distribution of siRNA 48 hours after injection is predictive of the longterm retention of siRNA 38 . We therefore analyzed the distribution of lipid-conjugated siRNAs, 48 hours after injection, in 15 tissues: liver, kidneys, adrenal glands, lung, heart, thymus, spleen, pancreas, intestine, fallopian tube, bladder, fat, muscle, injection site, and skin. Supplementary As expected, conjugated siRNAs accumulated in primary clearance tissues (kidneys and liver), at the injection site, and in other tissues with discontinuous or fenestrated epithelia (e.g., spleen). We observed a clear relationship between siRNA lipophilicity and the amount of siRNA that accumulated in these tissues. For example, low lipophilic siRNAs (DHA-, EPA-, RA-, and LA-siRNAs, and PC-conjugated derivatives) accumulated to higher levels in kidneys than in the liver or spleen or at the injection site (Figure 2, Supplementary Figures 1, 2, 3 and 14) . By contrast, high lipophilic siRNAs (TS-, DCA-, and Chol-siRNAs, and PC-conjugated derivatives) showed limited kidney distribution (Figure 2b ) and accumulated to higher levels in liver and spleen and at the site of injection than low lipophilic siRNAs (Figure 2a ). Unconjugated siRNAs also accumulated to high levels in kidneys, due to the presence of phosphorothioate linkages 25, 39, 40 . The retention of high lipophilic siRNAs at the injection site agrees with a recent study comparing the clearance kinetics of PC-DHA-and cholesterol-conjugated siRNAs 38 .
Although the highest levels of siRNA were detected in liver and kidneys, significant levels of siRNA were detected in other major tissues, including heart (~20 ng/mg), lung (~29 ng/mg), muscle (~9 ng/mg), fat (~4 ng/mg), bladder (~5 ng/mg), spleen (~56 ng/mg), and adrenal glands (~20 ng/mg) ( Supplementary Figures 3-7, 11, 13 ). In most tissues, high lipophilic siRNAs accumulated to the highest levels. Thus, lipid moities allowed siRNA delivery to tissues throughout the body.
Lipid structure also affected siRNA distribution within tissues. In kidneys, siRNAs primarily accumulated in proximal epithelia, consistent with its role in filtration ( Supplementary Figure 2) . Nevertheless, some lipid-conjugated siRNAs (e.g. PC-RA-or EPA-siRNAs) accumulated to low but detectable levels in medulla, glomerulus and bowel capsule.
The effect of lipid conjugate was even more striking in liver (Supplementary Figure 1) . For example, cholesterol-conjugated siRNA variants were detected in all liver cell types, including Kupffer cells, endothelial cells, and hepatocytes. DCA-conjugated siRNAs were also detected in all three cell types, but its levels in Kupffer and endothelial cells appeared to be higher than in hepatocytes. Low lipophilic conjugates, e.g. DHA, were mostly detected in endothelial cells.
The tissues that we analyzed comprise most of the mouse body, and the relative mass of each tissue has been experimentally defined or estimated [41] [42] [43] . Our ability to quantify the concentration of siRNAs in tissues therefore allowed us to estimate the fraction of the injected dose of siRNA retained 48 hours after injection and the fraction of retained siRNA per tissue (Figure 3 ). Based on these calculations, we estimated near complete retention (>70%) of high lipophilic compounds (Figure 3a) , because only a small fraction of the injected dose was accumulated to and cleared though kidneys (Figure 3b) . By contrast, for most low lipophilic compounds, mice retained less than 60% of the injected dose, and most of the retained dose resided in the kidneys (Figure 3) , showing important renal clearance. Only 15% of unconjugated siRNAs were retained, and ~60% of the retained dose resided in kidneys (Figure 3) . This analysis revealed one notable outlier: mice retained <50% of the high lipophilicity PC-Chol-siRNA, with ~70% of the retained dose residing in liver. Aside from reducing the lipophilicity of lipid-conjugated siRNAs, the PC polar head group had variable effects on the clearance and tissue accumulation of siRNAs. The addition of a PC moiety increased the overall retention of TS-, DHA-, and RA-conjugated siRNAs, but increased the clearance of DCA-, Chol-, and LA-conjugated siRNAs (Figure 3a) . Nevertheless, the addition of a PC head group appeared to improve the retention of RA-, Chol-and DCAconjugated siRNAs in tissues other than liver, site of injection and kidneys (Figure 3b) . Indeed, the PC-DCA-siRNA conjugate showed the highest level of retention (17% of retained dose) in non-clearance tissues. These results suggest that although clearance of siRNA is inversely related to lipophilicity, some conjugates regulate clearance and distribution by as yet unknown mechanisms.
Lipid-conjugated siRNAs enable functional gene silencing in several extra-hepatic tissues, including heart, lung, muscle, fat, adrenal glands, and kidneys
To determine if lipid-conjugated siRNAs accumulate to levels sufficient for productive silencing, we injected mice subcutaneously with lipid-conjugated siRNAs targeting Huntingtin (Htt) 17 or Cyclophilin B (Ppib) 44 mRNAs. We chose these targets because validated siRNA sequences are available, both targets are widely expressed in the body, and both targets are expressed at different levels (Htt low, and Ppib high). We injected each conjugated siRNA at a dose of 20 mg/kg (16 mice per conjugate including non-targeting controls), and a week later we measured Ppib, Htt, and Hprt (hypoxanthine-guanine phosphoribosyl transferase, serving as a housekeeping gene) mRNA levels. At the dose tested (20 mg/kg), all conjugated siRNAs were well tolerated: we observed no adverse events or changes in blood chemistry ( Supplementary   Figure 31 ). For tissues that retained, for the majority of the compounds, more than 5 ng of conjugated siRNA per mg of tissue (liver, kidney, skin injection site, spleen, adrenal glands, heart, lung, and skin), we measured the activity of all 15 conjugated siRNAs and the unconjugated siRNA. For the remaining organs (intestine, bladder, fat, muscle, pancreas, thymus, and fallopian tube), we only measured the activity of conjugated siRNAs that accumulated to the highest level, level dependent on the tissue. In total, we processed around 3,000 samples. The silencing efficiency of each compound in each tissue is shown in Supplementary Figures 16 to 30 , and data are summarized as heat maps in Figure 4 . In all cases, non-targeting controls (Ntc) showed no significant reduction in target gene expression, indicating that the observed silencing is due to sequence specific effects rather than the general chemical scaffold. Unconjugated siRNAs only induced silencing in kidneys, demonstrating that statistically significant silencing depends on conjugate-mediated delivery (Figure 4, Supplementary   Figures 16-30) . With one exception, all of the conjugated siRNAs induced statistically significant downregulation of Htt or Ppib at the injection site (Figure 4, Supplementary Figure   22 ). Despite a high level of retention, RA-siRNA was the only conjugate that failed to silence either target at the injection site. Similarly, most of the conjugated compounds (except PC-, and PC-LA-siRNAs) induced silencing of Htt or Ppib in the liver (Figure 4, Supplementary Figure   16 ). In addition to liver and injection site (skin), in general, high lipophilic siRNAs induced significant levels of silencing in spleen (24% to 30% for Htt; 18% to 31% for Ppib) and adrenal glands (20% to 34% for Htt; 24% to 36% for Ppib) (Figure 4, Supplementary Figures 18, 21) .
Low lipophilic siRNAs showed significant silencing activity in kidneys (Figure 4,   Supplementary Figure 17) .
To examine the relationship between siRNA accumulation and efficacy in tissues, we plotted the level of silencing against the tissue concentration for each compound (Figure 5) . This analysis again clearly shows relationships between lipophilicity and tissue accumulation of conjugated siRNAs, as low and high lipophilic siRNAs tended to cluster separately. We also observed a moderate positive correlation between siRNA accumulation and silencing activity in several tissues (r = 0.53 to 0.75, Figure 5b) , but the correlation did not always hold for both targets. Moreover, different compounds sometimes showed dramatically different activities, even if they were present at similar concentrations. In liver, for example, PCand PC-EPA-siRNAs accumulated to similar levels (31 ng/mg vs. 36 ng/mg). However, whereas PC-EPA-siRNA induced ~50% silencing, PC-siRNA was completely inactive. Conversely, liver accumulation of DCA-siRNA was 10-fold higher (357 ng/mg) than that of PC-EPA-siRNA, but both compounds induced similar levels of silencing. A similar trend was observed in other tissues (Figure 5a) . These findings suggest that the structure of the lipid conjugate can have a profound effect on the biological activity of siRNAs within a tissue.
The threshold of lipid-conjugated siRNA required to down-regulate Ppib or Htt was also tissue-dependent. Whereas tissue concentrations of siRNA greater than 250 ng/mg were required for silencing in kidney tissue, concentrations between 20 and 60 ng/mg induced silencing in spleen (Figure 5a) . Even lower concentrations of siRNA were sufficient to induce potent silencing in fat (4 ng/mg) and muscle (7 to 9 ng/mg) (Supplementary Figures 11, 13, 25-26 ).
This analysis also showed that Htt and Ppib were more or less sensitive to silencing depending on the tissue. For example, Ppib was more effectively silenced than Htt at the injection site,
whereas Htt was more effectively silenced than Ppib in adrenal glands, likely due to differences in relative levels of gene expression in the targeted cellular population (Figure 5a) . Thus, in addition to the structure of the compound, the biology of the tissue affects the mechanism of uptake and biological availability.
These results suggest that (i) the amount of siRNAs required to induce silencing is tissue dependent, (ii) in some tissues a large amount of siRNA is not necessary to induce silencing, and (iii) over a certain amount of siRNAs in the tissue, a portion of the siRNAs is trapped in a nonproductive pathway 45, 46 .
DCA and PC-DCA-conjugated siRNAs enable wide-spread silencing
Several compounds, particularly DCA and PC-DCA-conjugated siRNAs, accumulated to significant levels in tissues other than liver and kidney (Figure 5c, Figures 6a-6d) , where they induced productive silencing (Figure 5c, Figures 6e-6f) . The degree of silencing depended on the target, but both DCA-and PC-DCA-conjugated siRNAs were able to significantly silence Htt or Ppib in heart, lung, adrenal glands, muscle, and fat. Depending on the tissue, the PC group either reduced, increased or unchanged Htt or Ppib silencing. Taken together, our findings indicate that a single subcutaneous injection of DCA-or PC-DCAconjugated siRNAs supports functional target regulation in multiple tissues throughout the body, opening these tissues to RNAi-based functional genomics studies.
Discussion
GalNAc-conjugated siRNAs have dominated the recent development of therapeutic oligonucleotides for liver indications. The GalNAc moiety drives specific delivery to and activity in hepatocytes [4] [5] [6] . We have shown that lipid conjugates support much broader delivery of siRNAs and enable functional silencing in many tissues, including liver, kidneys, lung, heart, muscle, spleen, fat, and adrenal glands. To our knowledge, only one other study has reported siRNA delivery to muscle after systemic injection 13 . At the dose tested, we did not observe overt toxicity or abnormal blood chemistry. Our findings suggest that, with careful selection, lipid conjugates promise to advance the therapeutic potential of siRNA.
For siRNAs to be delivered throughout the body, they must be retained. Lipid conjugates were essential for retention of siRNA in the body. Indeed, ~85% of unconjugated siRNA was rapidly cleared from the body, and most of the retained siRNA accumulated in kidneys.
Unconjugated siRNAs are ~13 kDa-well within the limit (approximately 40 kDa) filtered by the kidney. Clearance is affected by the nature of the conjugate and is slower for high lipophilic compounds 38 . Here we estimate that whereas retention of low lipophilic compounds varied from 27% to 62% of the injected compound, high lipophilic (e.g., cholesterol, DCA, and α-tocopheryl succinate) siRNA conjugates are almost completely retained by the body. The ability of lipophilic conjugates to bind to serum proteins is known to define in vivo distribution of small molecules. Indeed, lipid conjugates have a profound impact on siRNA binding to serum proteins, which correlates with observed tissue distribution pattern 11 (Osborn et al., 2018, in preparation) .
Future studies are needed to identify additional mechanisms that contribute to the in vivo retention and distribution of siRNAs.
The potential for widespread delivery of siRNAs comes with shortcomings. Lipidconjugated siRNAs are not delivered to specific tissues, and most of the injected dose will be delivered to primary clearance tissues, including liver, kidney, and spleen. Nevertheless, lipid-siRNA conjugates could be used to silence relevant targets that are only expressed in the disease tissue, or to silence disease targets that are widely expressed as long as the loss of activity is tolerated in healthy tissues. For example, fully chemically stabilized chol-conjugated siRNAs have been used to silence soluble FTL1, which is overexpressed in placentas of pregnant subjects with preeclampsia (Turanov et al., 2018, under review). Though the chol-siRNA targeting sFLT1 is efficiently delivered to placenta (~8% of injected dose), it also accumulates to liver and kidneys where silencing of sFLT1 is believed to be tolerated and irrelevant for disease progression. There are targets of the similar nature, including DUX4 in muscular dystrophy 47 .
Thus, use of lipophilic conjugates offers a potential for modulation of gene expression in many tissues, as long as target and clinical indication are carefully considered and matched to the pharmacologic and safety profile of the lipid-siRNA conjugate.
Lipid-based nanoparticles (LNP) have been explored as a way to deliver siRNA for decades. Years of chemical evolution have substantially improved LNPs efficacy and safety 9, 48 .
The size of an LNP particle has a dramatic effect on distribution, with liver being a predominant target tissue 49 . Indeed, differences in fenestrated capillary between tissues lead to the extravasation of particles with different diameters: ~2 nm in heart, muscle, lung, and skin; ~30 nm in kidneys; and ~150 nm in liver and spleen. The direct attachment of lipids to siRNAs supports delivery to a much wider array of tissues, because lipid-siRNA conjugates behaves more like small molecules bound to the serum proteins.
This study reports a first example of chemically engineered lipid-conjugated siRNAs for systemic delivery. Future expansion of the chemical space of lipophilic moieties will establish a path towards enhancing siRNA delivery and potency.
Methods
Synthesis of lipid functionalized solid support for the preparation of conjugated siRNAs
Lipid moieties (except α-tocopheryl succinate) were directly attached via a peptide bond to a controlled pore glass (CPG) functionalized by a C7 linker, as described 50 . To synthesize phosphocholine derivatives, amino C7 CPG was first functionalized with phosphocholine essentially as described 33 . Briefly, Fmoc-L-serine tert-butyl (TCI America) was phosphitylated using 2´-cyanoethyl-N,N-diisopropylchlorophosphoramidite (ChemGenes). The resulting phosphoramidite was coupled to choline p-toluenesulfonate (Alfa Aesar) using 5-(ethylthio)-1Htetrazole (ETT) as an activator. The phosphine ester was then oxidized, and the carboxylic acid and phosphate ester groups were deprotected (i.e., tert-butyl and cyanoethyl groups removed).
The resulting intermediate was attached to the amino C7 CPG via a peptide bond to form phosphocholine-functionalized CPG. The Fmoc group was then removed, and the selected lipid moiety was attached via a peptide bond to the CPG. All lipid-functionalized solid supports were obtained with a loading of 55 μmol/g. Three volumes 95% (v/v) ethanol were added, and the mixture was vortexed and then placed for 1h at -80°C. The solution was pelleted by centrifugation for 30 minutes at 5200 × g. The pellet containing the lipid-conjugated siRNA sense strand was dissolved in water, purified, and desalted as described below.
Synthesis of α-tocopheryl succinate-conjugated siRNAs
Oligonucleotide synthesis
An Expedite ABI DNA/RNA synthesizer was used to synthesize oligonucleotides following standard protocols. Sense strands were synthesized at 10 µmole scales on lipid-functionalized CPG or amino C7 CPG (for the post-synthetic conjugation of α-tocopheryl succinate moiety) supports. Antisense strands were synthesized at 10 µmole scales on CPG functionalized with 
Fluorescence microscopy
At 48-hours post-injection, mice were euthanized and perfused with PBS. Tissues were collected and immersed in 10% formalin solution overnight at 4°C. Tissues were embedded in paraffin and sliced into 4-μm sections that were mounted on glass slides. Tissue sections on glass slides were deparaffinized by incubating twice in xylene for 8 min. Sections were rehydrated in an ethanol series from 100% to 95% to 80%, for 4 min each. Slides were then washed twice with PBS, 2 min each, incubated with DAPI (250 ng/mL, Molecular Probes) in PBS for 1 minute, and washed again in PBS for 2 minutes. Slides were mounted with PermaFluor mounting medium (Molecular Probes) coverslips, and dried overnight at 4°C. Sections were imaged at 5× and 40× using a Leica DM5500B microscope fitted with a DFC365 FX fluorescence camera.
Peptide nucleic acid (PNA) hybridization assay
Tissue concentrations of antisense strands were determined using a PNA hybridization assay 37, 38 .
Tissues (15 mg) were placed in QIAGEN Collection Microtubes holding 3-mm tungsten beads and lysed in 300 µl MasterPure tissue lysis solution (EpiCentre) containing 0.2 mg/ml proteinase K (Invitrogen) using a QIAGEN TissueLyser II. Lysates were then centrifuged at 1,000 × g for 10 min and incubated for 1 h at 55° to 60°C. Sodium dodecyl sulphate (SDS) was precipitated from lysates by adding 20 µL 3 M potassium chloride and pelleted centrifugation at 5000 × g for 15 minutes. Conjugated siRNAs in cleared supernatant were hybridized to a Cy3-labeled PNA probe fully complementary to the antisense strand (PNABio, Thousand Oaks, CA, USA).
Samples were analyzed by HPLC (Agilent, Santa Clara, CA) over a DNAPac PA100 anion-exchange column (Thermo Fisher Scientific), in a gradient of sodium perchlorate, as follows:
Buffer A: 50% water; 50% acetonitrile; 25 mM Tris-HCl, pH 8.5; 1 mM ethylenediaminetetraacetate. Buffer B: 800 mM sodium perchlorate in buffer A. Gradient conditions: 10% buffer B within 4 min, 50% buffer B for 1 min, and 50% to 100% buffer B within 5 minutes. Cy3 fluorescence was monitored and peaks integrated. Final concentrations were ascertained using calibration curves generated by spiking known quantities of lipidconjugated siRNA into tissue lysates from an untreated animal. Spiked samples for calibration and experimental samples were processed and analyzed under the same laboratory conditions.
In vivo mRNA silencing experiments
At 1-week post-injection, mice were euthanized and perfused with PBS. Tissues were collected and stored in RNAlater (Sigma) at 4°C overnight. mRNA was quantified using the QuantiGene 2.0 Assay (Affymetrix). 1.5-mm punches (3 punches per tissue) were placed in QIAGEN Collection Microtubes holding 3-mm tungsten beads and lysed in 300 μl Homogenizing Buffer (Affymetrix) containing 0.2 mg/ml proteinase K (Invitrogen) using a QIAGEN TissueLyser II.
Samples were then centrifuged at 1,000 × g for 10 min and incubated for 1 h at 55° to 60°C.
Lysates and diluted probe sets (mouse Htt, mouse Ppib, or mouse Hprt) were added to the bDNA capture plate and signal was amplified and detected as described by Coles et al 51 . Luminescence was detected on a Tecan M1000 (Tecan, Morrisville, NC, USA).
Statistical analysis
Data were analyzed using GraphPad Prism 7.01 software (GraphPad Software, Inc., San Diego, CA). For each independent mouse experiment, the level of silencing was normalized to the mean of the control group (PBS group). Data were analyzed using non-parametric one-way ANOVA with Bonferroni's test for multiple comparisons, with significance calculated relative to both PBS controls and non-targeting controls (Ntc). 
Figure legends
